Table 2:
Putative: therapeutic targets for hypertension and their potential drugs discussed in the present manuscript.
| Target | Potential drugs | Observed effect | Reference |
|---|---|---|---|
| NHE3 | SAR218034 | Reduction in blood pressure in Spontaneously Hypertensive rats | [44] |
| Tenapanor | Blockage of absorption of ingested sodium with minimal systemic effects | [44, 45] | |
| AVE-0657 | Induction of natriuresis, impaired hypertensive response in Ang II–infused, 2% high salt-fed C57BL/6 J mice without changes in faecal Na+ excretion | [26, 34, 35] | |
| Empagliflozin (SGLT2 inhibitor) | Reduction of NHE3 transport activity in rats and mice | [46, 47] | |
| SPAK (CUL3/KLHL3–WNK1/4–SPAK/OSR1 regulatory cascade) | STOCK1S-50699 STOCK2S-26 016 | Inhibition of SPAK interaction to WNK, and inhibition on phosphorylation of SPAK and NCC | [92] |
| ZT-1a | Inhibitory effect on NCC phosphorylation in SPAK-dependent manner in mouse kidney | [93] |